Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC

Laryngoscope

Volumn 125, Issue 3, 2015, Pages E118-E124

  Eytan, Danielle F ^a,b,c   Snow, Grace E ^b,c   Carlson, Sophie G ^a   Schiltz, Stephen ^a   Chen, Zhong ^a   Van Waes, Carter ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Cell death; Inhibitor of apoptosis; Second mitochondria derived activator of caspases; Squamous carcinoma

Indexed keywords

BIRC2 PROTEIN; BIRINAPANT; DOCETAXEL; FAS ASSOCIATED DEATH DOMAIN PROTEIN; PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DIABLO PROTEIN, HUMAN; DIPEPTIDE; INDOLE DERIVATIVE; MITOCHONDRIAL PROTEIN; SIGNAL PEPTIDE; TAXOID; TUMOR NECROSIS FACTOR;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RESISTANCE; CANCER SIZE; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE M PHASE; CELL DEATH; CELL DENSITY; CELL PROLIFERATION ASSAY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; EXPERIMENTAL STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IC50; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; ANIMAL; CARCINOMA, SQUAMOUS CELL; CELL COUNT; CELL PROLIFERATION; COMBINATION DRUG THERAPY; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMAN; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; DIPEPTIDES; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MITOCHONDRIAL PROTEINS; NEOPLASMS, EXPERIMENTAL; TAXOIDS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923360677     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.25056     Document Type: Article

References (24)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Long JS, Ryan KM. New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy. Oncogene 2012;31:5045-5060.
3. Oberst A, Green DR. It cuts both ways: reconciling the dual roles of caspase 8 in cell death and survival. Nat Rev Mol Cell Biol 2011;12:757-763.
4. Katherine A. Hoadley CF, Matthew D. Wilkerson, et al. Multi-tumor analysis of TCGA data identifies expression commonalities across tumor types. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2013.
5. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010;10:561-574.
6. Tanimoto T, Tsuda H, Imazeki N, et al. Nuclear expression of cIAP-1, an apoptosis inhibiting protein, predicts lymph node metastasis and poor patient prognosis in head and neck squamous cell carcinomas. Cancer Lett 2005;224:141-151.
7. Qi S, Mogi S, Tsuda H, et al. Expression of cIAP-1 correlates with nodal metastasis in squamous cell carcinoma of the tongue. Int J Oral Maxillofac Surg 2008;37:1047-1053.
8. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012;11:109-124.
9. Varfolomeev E, Blankenship JW, Wayson SM, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007;131:669-681.
10. Benetatos CA, Mitsuuchi Y, Burns JM, et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNFinduced NF-kappaB activation, and is active in patient-derived xenograft models. Mol Cancer Ther 2014;13:867-879.
11. Allensworth JL, Sauer SJ, Lyerly HK, Morse MA, Devi GR. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-alphaindependent mechanism. Breast Cancer Res Treat 2013;137:359-371.
12. Condon SM, Mitsuuchi Y, Deng Y, et al. Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. J Med Chem 2014;57:3666-3677.
13. Krause CJ, Carey TE, Ott RW, Hurbis C, McClatchey KD, Regezi JA. Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines. Arch Otolaryngol 1981;107:703-710.
14. Carey TE. Establishment of epidermoid carcinoma cell lines. In: RE W, ed. Head and Neck Cancer. New York, NY: John Wiley & Sons Inc; 1985;289-316.
15. Bradshaw-Pierce EL, Steinhauer CA, Raben D, Gustafson DL. Pharmacokineticdirected dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma. Mol Cancer Ther 2008;7:3006-3017.
16. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-446.
17. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, Neckers L. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res 1995;55:4623-4626.
18. Bradford CR, Zhu S, Ogawa H, et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 2003;25:654-661.
19. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007;357:2552-2561.
20. Wakelee HA, Patnaik A, Sikic BI, et al. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 2010;21:376-381.
21. Forero-Torres A, Shah J, Wood T, et al. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm 2010;25:13-19.
22. Camidge DR. Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors. Expert Opin Biol Ther 2008;8:1167-1176.
23. Beug ST, Tang VA, La Casse EC, et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat Biotechnol 2014;32:182-190.
24. Xanthinaki A, Nicolatou-Galitis O, Athanassiadou P, et al. Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report. Support Care Cancer 2008;16:1025-1033.